Assessment and Management of Platinum-Related Ototoxicity in Children Treated for Cancer
Abstract
1. Introduction
2. Pathogenesis of Hearing Damage from Platinum Compounds
3. Assessment of the Hearing Function during Treatment with Platinum Compounds
4. Audiological Follow-Up after Therapy with Platinum Compounds
5. Strategies of Prevention of Hearing Loss
6. Conclusions
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Knight, K.R.; Kraemer, D.F.; Neuwelt, E.A. Ototoxicity in children receiving platinum chemotherapy: Underestimating a commonly occurring toxicity that may influence academic and social development. J. Clin. Oncol. 2005, 23, 8588–8596. [Google Scholar] [CrossRef]
- Van den Berg, H.; Van den Anker, J.N.; Beijnen, J.H. Cytostatic drugs in infants: A review on pharmacokinetic data in infants. Cancer Treat Rev. 2012, 18, 3–26. [Google Scholar] [CrossRef]
- Ruggiero, A.; Trombatore, G.; Triarico, S.; Arena, R.; Ferrara, P.; Scalzone, M.; Pierri, F.; Riccardi, R. Platinum compounds in children with cancer: Toxicity and clinical management. Anticancer Drugs 2013, 24, 1007–1019. [Google Scholar] [CrossRef]
- Boulikas, T.; Pantos, A.; Bellis, E.; Petros, C. Designing platinum compounds in cancer: Structures and mechanisms. Cancer Ther. 2007, 5, 537–583. [Google Scholar]
- O’Dwyer, P.J.; Stevenson, J.P.; Johnson, S.W. Clinical pharmacokinetics and administration of established platinum drugs. Drugs 2000, 59, 19–27. [Google Scholar] [CrossRef]
- Lokich, J.; Anderson, N. Carboplatin versus cisplatin in solid tumors: An analysis of the literature. Ann. Oncol. 1998, 9, 13–21. [Google Scholar] [CrossRef]
- Peng, B.; English, M.W.; Boddy, A.V.; Price, L.; Wyllie, R.; Pearson, A.D.J.; Tilby, M.J.; Newell, D.R. Cisplatin pharmacokinetics in children with cancer. Eur. J. Cancer 1997, 33, 1823–1828. [Google Scholar] [CrossRef]
- Go, R.S.; Adjei, A.A. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J. Clin. Oncol. 1999, 17, 409–422. [Google Scholar] [CrossRef]
- Breglio, A.M.; Rusheen, A.E.; Shide, E.D.; Fernandez, K.A.; Spielbauer, K.K.; McLachlin, K.M.; Hall, M.D.; Amable, L.; Cunningham, L.L. Cisplatin is retained in the cochlea indefinitely following chemotherapy. Nat. Commun. 2017, 8, 1654. [Google Scholar] [CrossRef]
- UpToDate. Cisplatin: Drug Information. Available online: http://www.uptodate.com (accessed on 30 March 2020).
- Pussegoda, K.; Ross, C.J.; Visscher, H.; Yazdanpanah, M.; Brooks, B.; Rassekh, S.R.; Zada, Y.F.; Dubé, M.P.; Carleton, B.C.; Hayden, M.R.; et al. Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children. Clin. Pharmacol. Ther. 2013, 94, 243–251. [Google Scholar] [CrossRef]
- Nakamura, T.; Yonezawa, A.; Hashimoto, S.; Katsura, T.; Inui, K. Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity. Biochem. Pharmacol. 2010, 80, 1762–1767. [Google Scholar] [CrossRef]
- Kanat, O.; Ertas, H.; Caner, B. Platinum-induced neurotoxicity: A review of possible mechanisms. World J. Clin. Oncol. 2017, 8, 329–335. [Google Scholar] [CrossRef]
- Knox, R.J.; Friedlos, F.; Lydall, D.A.; Roberts, J.J. Mechanism of cytotoxicity of anticancer platinum drugs: Evidence that cis-diam-minedi-chloroplatinum (II) and cis-diammine (1,1-cyclobutane-diacarbo-xylate) platinum (II) differ only in kinetics of their interaction with DNA. Cancer Res. 1986, 46, 1972–1979. [Google Scholar]
- Micetich, K.C.; Barnes, D.; Erickson, L.C. A comparative study of the cytotoxicity and DNA-damaging effects of cis-(diammino) (1,1- cyclobutanedicarboxylato)-platinum (II) and cis-diamminedichloroplatinum (II) on L1210 cells. Cancer Res. 1985, 45, 4043–4047. [Google Scholar]
- UpToDate. Carboplatin: Drug information. Available online: http://www.uptodate.com (accessed on 30 March 2020).
- Veal, G.J.; Errington, J.; Tilby, M.J.; Pearson, A.D.; Foot, A.B.; McDowell, H.; Ellershaw, C.; Pizer, B.; Nowell, G.M.; Pearson, D.G.; et al. Adaptive dosing and platinum–DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours. Br. J. Cancer 2007, 96, 725–731. [Google Scholar] [CrossRef]
- Lebwohl, D.; Canetta, R. Clinical development of platinum complexes in cancer therapy: An historical perspective and an update. Eur. J. Cancer 1998, 34, 1522–1534. [Google Scholar] [CrossRef]
- Kweekel, D.M.; Gelderblom, H.; Guchelaar, H.J. Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat. Rev. 2005, 31, 90–105. [Google Scholar] [CrossRef]
- Di Francesco, A.M.; Ruggiero, A.; Riccardi, R. Cellular and molecular aspects of drugs of the future: Oxaliplatin. Cell. Mol. Life Sci. 2002, 59, 1914–1927. [Google Scholar] [CrossRef]
- Page, J.D.; Husain, I.; Sancar, A.; Chaney, S.G. Effect of the diaminocyclohexane carrier ligand on platinum adduct formation, repair, and lethality. Biochemistry 1990, 29, 1016–1024. [Google Scholar] [CrossRef]
- Fink, D.; Nebel, S.; Aebi, S.; Zheng, H.; Cenni, B.; Nehme, A.; Christen, R.D.; Howell, S.B. The role of DNA mismatch repair in platinum drug resistance. Cancer Res. 1996, 56, 4881–4886. [Google Scholar]
- Vaisman, A.; Varchenko, M.; Umar, A.; Kunkel, T.A.; Risinger, J.I.; Barrett, J.C.; Hamilton, T.C.; Chaney, S.G. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: Correlation with replicative bypass of platinum–DNA adducts. Cancer Res. 1998, 58, 3579–3585. [Google Scholar]
- Raymond, E.; Lawrence, R.; Izbicka, E.; Faivre, S.; Von Hoff, D.D. Activity of oxaliplatin against human tumor colony forming units. Clin. Cancer Res. 1998, 4, 1021–1029. [Google Scholar]
- Riccardi, A.; Ferlini, C.; Meco, D.; Mastrangelo, R.; Scambia, G.; Riccardi, R. Antitumor activity of oxaliplatin in neuroblastoma cell lines. Eur. J. Cancer 1999, 35, 86–90. [Google Scholar] [CrossRef]
- Bass, J.K.; Knight, K.R.; Yock, T.I.; Chang, K.W.; Cipkala, D.; Grewal, S.S. Evaluation and management of hearing loss in survivors of childhood and adolescent cancers: A report from the children’s oncology group. Pediatr. Blood Cancer 2016, 63, 1152–1162. [Google Scholar] [CrossRef]
- Bertolini, P.; Lassalle, M.; Mercier, G.; Raquin, M.A.; Izzi, G.; Corradini, N.; Hartmann, O. Platinum compound-related ototoxicity in children: Long-term follow-up reveals continuous worsening of hearingloss. J. Pediatr. Hematol. Oncol. 2004, 26, 649–655. [Google Scholar] [CrossRef]
- Hua, C.; Bass, J.K.; Khan, R.; Kun, L.E.; Merchant, T.E. Hearing loss after radiotherapy for Pediatric brain tumors: Effect of cochlear dose. Int. J. Radiat. Oncol. Biol. Phys. 2008, 72, 892–899. [Google Scholar] [CrossRef]
- Kolinsky, D.C.; Hayashi, S.S.; Karzon, R.; Mao, J.; Hayashi, R.J. Late onset hearing loss: A significant complication of cancer survivors treated with cisplatin containing chemotherapy regimens. J. Pediatr. Hematol. Oncol. 2010, 32, 119–123. [Google Scholar] [CrossRef]
- Rybak, L.P.; Whitworth, C.A.; Mukherjea, D.; Ramkumar, V. Mechanisms of cisplatin-induced ototoxicity and prevention. Hear. Res. 2007, 226, 157–167. [Google Scholar] [CrossRef]
- Langer, T.; Zehnhoff-Dinnesen, A.; Radtke, S.; Meitert, J.; Zolk, O. Understanding platinum-induced ototoxicity. Trends Pharmacol. Sci. 2013, 34, 458–469. [Google Scholar] [CrossRef]
- Brock, P.R.; Knight, K.R.; Freyer, D.R.; Campbell, K.C.; Steyger, P.S.; Blakley, B.W.; Rassekh, S.R.; Chang, K.W.; Fligor, B.J.; Rajput, K.; et al. Platinum-induced ototoxicity in children: A consensus review on mechanisms, predisposition, and protection, including a new international society of Pediatric oncology Boston ototoxicity scale. J. Clin. Oncol. 2012, 30, 2408–2417. [Google Scholar] [CrossRef]
- Kopke, R.D.; Liu, W.; Gabaizadeh, R.; Jacono, A.; Feghali, J.; Spray, D.; Garcia, P.; Steinman, H.; Malgrange, B.; Ruben, R.J.; et al. Use of organotypic cultures of Corti’s organ to study the protective effects of antioxidant molecules on cisplatin-induced damage of auditory hair cells. Am. J. Otol. 1997, 18, 559–571. [Google Scholar] [PubMed]
- Dehne, N.; Lautermann, J.; Petrat, F.; Rauen, U.; de Groot, H. Cisplatin ototoxicity: Involvement of iron and enhanced formation of superoxide anion radicals. Toxicol. Appl. Pharmacol. 2001, 174, 27–34. [Google Scholar] [CrossRef] [PubMed]
- Bánfi, B.; Malgrange, B.; Knisz, J.; Steger, K.; Dubois-Dauphin, M.; Krause, K.H. NOX3, a superoxide-generating NADPH oxidase of the inner ear. J. Biol. Chem. 2004, 279, 46065–46072. [Google Scholar] [CrossRef] [PubMed]
- Rybak, L.P.; Mukherjea, D.; Ramkumar, V. Mechanisms of cisplatin-induced ototoxicity and prevention. In Seminars in Hearing; Thieme Medical Publishers: New York, NY, USA, 2019; Volume 40, pp. 197–204. [Google Scholar] [CrossRef]
- Rybak, L.P.; Husain, K.; Morris, C.; Whitworth, C.; Somani, S. Effect of protective agents against cisplatin ototoxicity. Am. J. Otol. 2000, 21, 513–520. [Google Scholar]
- Paciello, F.; Fetoni, A.; Mezzogori, D.; Rolesi, R.; Di Pino, A.; Paludetti, G.; Grassi, G.; Troiani, D. The dual role of curcumin and ferulic acid in counteracting chemoresistance and cisplatin-induced ototoxicity. Sci. Rep. 2020, 23, 1063. [Google Scholar] [CrossRef]
- Riedemann, L.; Lanvers, C.; Deuster, D.; Peters, U.; Boos, J.; Jürgens, H.; am Zehnhoff-Dinnesen, A. Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Pharm. J. 2008, 8, 23–28. [Google Scholar] [CrossRef]
- Xu, X.; Ren, H.; Zhou, B.; Zhao, Y.; Yuan, R.; Ma, R.; Zhou, H.; Liu, Z. Prediction of copper transport protein 1 (CTR1) genotype on severe cisplatin induced toxicity in non-small cell lung cancer (NSCLC) patients. Lung Cancer 2012, 77, 438–442. [Google Scholar] [CrossRef]
- Brusilow, S.W.; Gordes, E. The mutual independence of the endolymphatic potential and the concentrations of sodium and potassium in endolymph. J. Clin. Investig. 1973, 52, 2517–2521. [Google Scholar] [CrossRef]
- Altura, B.M.; Altura, B.T.; Gebrewold, A.; Ising, H.; Günther, T. Magnesium deficiency and hypertension: Correlation between magnesium deficient diets and microcirculatory changes in situ. Science 1984, 223, 1315–1317. [Google Scholar] [CrossRef]
- Brown, R. Ethacrinic acid and furosemide: Possible cochlear sites and mechanisms of ototoxic action. Mednikon 1975, 4, 33–40. [Google Scholar]
- Joachims, Z.; Babisch, W.; Ising, H.; Günther, T.; Handrock, M. Dependence of noise induced hearing loss on perilymph magnesim concentration. J. Acoust. Soc. Am. 1983, 74, 104–108. [Google Scholar] [CrossRef]
- Grewal, S.; Merchant, T.; Reymond, R.; McInerney, M.; Hodge, C.; Shearer, P. Auditory late effects of childhood cancer therapy: A report from the children’s oncology group. Pediatrics 2010, 125, e938–e950. [Google Scholar] [CrossRef] [PubMed]
- Huang, R.S.; Kistner, E.O.; Bleibel, W.K.; Shukla, S.J.; Dolan, M.E. Effect of population and gender on chemotherapeutic agent-induced cytotoxicity. Mol. Cancer Ther. 2007, 6, 31–36. [Google Scholar] [CrossRef] [PubMed]
- Martindale, J.L.; Holbrook, N.J. Cellular response to oxidative stress: Signaling for suicide and survival. J. Cell Physiol. 2002, 192, 1–15. [Google Scholar] [CrossRef] [PubMed]
- Faragher, A.J.; Fry, A.M. Nek2A kinase stimulates centrosome disjunction and is required for formation of bipolar mitotic spindles. Mol. Biol. Cell 2003, 14, 2876–2889. [Google Scholar] [CrossRef] [PubMed]
- Lin, C.P.; Liu, J.D.; Chow, J.M.; Liu, C.R.; Liu, H.E. Small-molecule c-Myc inhibitor, 10058-F4, inhibits proliferation, downregulates human telomerase reverse transcriptase and enhances chemosensitivity in human hepatocellular carcinoma cells. Anticancer Drugs 2007, 18, 161–170. [Google Scholar] [CrossRef]
- Peters, U.; Preisler-Adams, S.; Hebeisen, A.; Hahn, M.; Seifert, E.; Lanvers, C.; Heinecke, A.; Horst, J.; Jürgens, H.; Lamprecht-Dinnesen, A. Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Drugs 2000, 11, 639–643. [Google Scholar] [CrossRef]
- Oldenburg, J.; Kraggerud, S.M.; Cvancarova, M.; Lothe, R.A.; Fossa, S.D. Cisplatin-induced long-term hearing impairment is associated with specific glutathione S-transferase genotypes in testicular cancer survivors. J. Clin. Oncol. 2007, 25, 708–714. [Google Scholar] [CrossRef]
- Peters, U.; Preisler-Adams, S.; Lanvers-Kaminsky, C.; Jürgens, H.; Lamprecht-Dinnesen, A. Sequence variations of mitochondrial DNA and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Res. 2003, 23, 1249–1255. [Google Scholar]
- Knoll, C.; Smith, R.J.; Shores, C.; Blatt, J. Hearing genes and cisplatin deafness: A pilot study. Laryngoscope 2009, 116, 72–74. [Google Scholar] [CrossRef]
- Clemens, E.; Broer, L.; Langer, T.; Uitterlinden, A.G.; de Vries, A.C.H.; van Grotel, M.; Pluijm, S.F.M.; Binder, H.; Byrne, J.; Broeder, E.V.D.; et al. Genetic variation of cisplatin-induced ototoxicity in non-cranial-irradiated pediatric patients using a candidate gene approach: The International PanCareLIFE Study. Pharm. J. 2020, 20, 294–305. [Google Scholar] [CrossRef]
- Li, Y.; Womer, R.B.; Silber, J.H. Predicting cisplatin ototoxicity in children: The infl uence of age and the cumulative dose. Eur. J. Cancer 2004, 40, 2445–2451. [Google Scholar] [CrossRef] [PubMed]
- Lanvers-Kaminsky, C.; Zehnhoff-Dinnesen, A.A.; Parfitt, R.; Ciarimboli, G. Drug-induced ototoxicity: Mechanisms, pharmacogenetics, and protective strategies. Clin. Pharmacol. Ther. 2017, 101, 491–500. [Google Scholar] [CrossRef] [PubMed]
- Shi, X.; Nuttall, A.L. Upregulated iNOS and oxidative damage to the cochlear stria vascularis due to noise stress. Brain Res. 2003, 967, 1–10. [Google Scholar] [CrossRef]
- Ding, D.; Allman, B.L.; Salvi, R. Ototoxic characteristics of platinum antitumor drugs. Anat. Rec. 2012, 295, 1851–1867. [Google Scholar] [CrossRef] [PubMed]
- Gratton, M.A.; Salvi, R.J.; Kamen, B.A.; Saunders, S.S. Interaction of cisplatin and noise on the peripheral auditory system. Hear. Res. 1990, 50, 211–223. [Google Scholar] [CrossRef]
- Rabiço-Costa, D.; Gil-da-Costa, M.J.; Barbosa, J.P.; Bom-Sucesso, M.; Spratley, J. Platinum-drugs ototoxicity in Pediatric patients with brain tumors: A 10-year review. J. Pediatr. Hematol. Oncol. 2020, 42, e25–e31. [Google Scholar] [CrossRef]
- Khan, A.; Budnick, A.; Barnea, D.; Feldman, D.R.; Oeffinger, K.C.; Tonorezos, E.S. Hearing loss in adult survivors of childhood cancer treated with radiotherapy. Child. Basel 2018, 5, 59. [Google Scholar] [CrossRef]
- Bass, J.K.; Huang, J.; Onar-Thomas, A.; Chang, K.W.; Bhagat, S.P.; Chintagumpala, M.; Bartels, U.; Gururangan, S.; Hassall, T.; Heath, J.A.; et al. Concordance between the Chang and the International Society of Pediatric Oncology (SIOP) Ototoxicity Grading Scales in patients treated with cisplatin for medulloblastoma. Pediatr. Blood Cancer 2014, 61, 601–605. [Google Scholar] [CrossRef]
- Delpire, E.; Lu, J.; England, R.; Dull, C.; Thorne, T. Deafness and imbalance associated with inactivation of the secretory Na-K-2Cl co-transporter. Nat. Genet. 1999, 22, 192–195. [Google Scholar] [CrossRef]
- Farinetti, A.; Raji, A.; Wu, H.; Wanna, B.; Vincent, C. International consensus (ICON) on audiological assessment of hearing loss in children. Eur. Ann. Otorhinolaryngol. Head Neck Dis. 2018, 135, S41–S48. [Google Scholar] [CrossRef] [PubMed]
- Anastasio, A.R.; Radael, R.D.; Cavalcante, J.M.; Hatzopoulos, S. A report of extended high frequency audiometry thresholds in school-age children with no hearing complaints. Audiol. Res. 2012, 17, 2–8. [Google Scholar] [CrossRef]
- Hunter, L.L.; Monson, B.B.; Moore, D.R.; Dhar, S.; Wright, B.A.; Munro, K.J.; Zadeh, L.M.; Blankenship, C.M.; Stiepan, S.M.; Siegel, J.H.; et al. Extended High Frequency Hearing and Speech Perception Implications in Adults and Children. Hear. Res. 2020, 18, 107922. [Google Scholar] [CrossRef] [PubMed]
- Durrant, J.D.; Campbell, K.; Fausti, S.; Guthrie, O.; Jacobson, G.; Lonsbury-Martin, B.L.; Poling, G. American Academy of Audiology Position Statement and Clinical Practice Guidelines: Ototoxicity Monitoring. 2009. Available online: http://www.audiology.org/resources/documentlibrary/Documents/OtoMonGuidelines (accessed on 30 March 2020).
- Fausti, S.A.; Thompson, M.; Williams, J.; Bouchard, K.R.; Farrer, S.M.; Heifer, K.S.; McHaney, V.A.; Tysklind, J.M.; Durrant, J.; Fowler, C.; et al. Audiologic Management of Individuals Receiving Cochleotoxic Drug Therapy, American Speech-Language-Hearing Association. 1994. Available online: http://www.asha.org/policy/GL1994-00003.htm (accessed on 30 March 2020).
- Knight, K.R.; Chen, L.; Freyer, D.; Aplenc, R.; Bancroft, M.; Bliss, B.; Dang, H.; Gillmeister, B.; Hendershot, E.; Kraemer, D.F.; et al. Group-wide, prospective study of ototoxicity assessment in children receiving cisplatin chemotherapy (ACCL05C1): A report from the children’s oncology group. J. Clin. Oncol. 2017, 35, 440–445. [Google Scholar] [CrossRef]
- King, K.A.; Brewer, C.C. Clinical trials, ototoxicity grading scales, and the audiologist’s role in therapeutic decision making. Int. J. Audiol. 2018, 57, S89–S98. [Google Scholar] [CrossRef]
- Clemens, E.; van den Heuvel-Eibrink, M.M.; Mulder, R.L.; Kremer, L.C.M.; Hudson, M.M.; Skinner, R.; Constine, L.S.; Bass, J.K.; Kuehni, C.E.; Langer, T.; et al. International guideline harmonization group ototoxicity group. Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: A report from the international late effects of childhood cancer guideline harmonization group in collaboration with the pancare consortium. Lancet Oncol. 2019, 20, e29–e41. [Google Scholar] [CrossRef]
- Lewis, M.J.; Du Bois, S.G.; Fligor, B.; Li, X.; Goorin, A.; Grier, H.E. Ototoxicity in children treated for osteosarcoma. Pediatr. Blood Cancer 2009, 52, 387–391. [Google Scholar] [CrossRef]
- Peleva, E.; Emami, N.; Alzahrani, M.; Bezdjian, A.; Gurberg, J.; Carret, A.S.; Daniel, S.J. Incidence of platinum-induced ototoxicity in Pediatric patients in Quebec. Pediatr. Blood Cancer 2014, 61, 2012–2017. [Google Scholar] [CrossRef]
- Stöhr, W.; Langer, T.; Kremers, A.; Bielack, S.; Lamprecht-Dinnesen, A.; Frey, E.; Beck, J.D. german late effects working group in the german society of Pediatric oncology and hematology. Cisplatin-induced ototoxicity in osteosarcoma patients: A report from the late effects surveillance system. Cancer Investig. 2005, 23, 201–207. [Google Scholar] [CrossRef]
- Coradini, P.P.; Cigana, L.; Selistre, S.G.; Rosito, L.S.; Brunetto, A.L. Ototoxicity from cisplatin therapy in childhood cancer. J. Pediatr. Hematol. Oncol. 2007, 29, 355–360. [Google Scholar] [CrossRef]
- Fetoni, A.R.; Ruggiero, A.; Lucidi, D.; De Corso, E.; Sergi, B.; Conti, G.; Paludetti, G. Audiological monitoring in children treated with platinum chemotherapy. Audiol. Neurootol. 2016, 21, 203–211. [Google Scholar] [CrossRef] [PubMed]
- Stachler, R.J.; Chandrasekhar, S.S.; Archer, S.M.; Rosenfeld, R.M.; Schwartz, S.R.; Barrs, D.M.; Brown, S.R.; Fife, T.D.; Ford, P.; Ganiats, T.G.; et al. American academy of otolaryngology-head and neck surgery. Clinical practice guideline: Sudden hearing loss. Otolaryngol. Head Neck Surg. 2012, 146, S1–S35. [Google Scholar] [CrossRef] [PubMed]
- NICE: London. National Institute for Health and Care Excellence. Cochlear Implants for Children and Adults with Severe to Profound Deafness. 2009. Available online: https://www.nice.org.uk/guidance/ta166 (accessed on 30 March 2020).
- New York State Department of Health. Clinical Practice Guideline: Report of the Recommendations. Hearing Loss: Assessment and Intervention for Young Children (Age 0–3 Years). 2007. Available online: https://www.health.ny.gov/community/infants_children/early_intervention/docs/guidelines_hearing_loss_recommendations.pdf (accessed on 30 March 2020).
- American Association of Audiology. Clinical Practice Guidelines on Pediatric Amplification. 2013. Available online: http://galster.net/wp-content/uploads/2013/07/AAA-2013-Pediatric-Amp-Guidelines.pdf (accessed on 30 March 2020).
- Audiology Australia. Professional Practice Standards: Audiological Rehabilitation. 2013. Available online: https://audiology.asn.au/Tenant/C0000013/Position%20Papers/Member%20Resources/Clinical%20Standards%20partb%20-%20whole%20document%20July13%201 (accessed on 30 March 2020).
- Fetoni, A.R.; Paciello, F.; Mezzogori, D.; Rolesi, R.; Eramo, S.L.; Paludetti, G.; Troiani, D. Molecular targets for anticancer redox chemotherapy and cisplatin-induced ototoxicity: The role of curcumin on pSTAT3 and Nrf-2 signalling. Br. J. Cancer 2015, 113, 1434–1444. [Google Scholar] [CrossRef] [PubMed]
- Fetoni, A.R.; Eramo, S.L.; Paciello, F.; Rolesi, R.; Podda, M.V.; Troiani, D.; Paludetti, G. Curcuma longa (curcumin) decreases in vivo cisplatin-induced ototoxicity through heme oxygenase-1 induction. Otol. Neurotol. 2014, 35, e169–e177. [Google Scholar] [CrossRef]
- Fetoni, A.R.; Sergi, B.; Ferraresi, A.; Paludetti, G.; Troiani, D. Protective effects of alpha-tocopherol and tiopronin against cisplatin-induced ototoxicity. Acta Otolaryngol. 2004, 124, 421–426. [Google Scholar] [CrossRef]
- Lafay-Cousin, L.; Purdy, E.; Huang, A.; Cushing, S.L.; Papaioannou, V.; Nettel-Aguirre, A.; Bouffet, E. Early cisplatin induced ototoxicity profile may predict the need for hearing support in children with medulloblastoma. Pediatr. Blood Cancer 2013, 60, 287–292. [Google Scholar] [CrossRef]
- Van As, J.W.; van den Berg, H.; van Dalen, E.C. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer. Cochrane Database Syst. Rev. 2012, 16, CD009219. [Google Scholar] [CrossRef]
- Fouladi, M.; Chintagumpala, M.; Ashley, D.; Kellie, S.; Gururangan, S.; Hassall, T.; Gronewold, L.; Stewart, C.F.; Wallace, D.; Broniscer, A.; et al. Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma. J. Clin. Oncol. 2008, 26, 3749–3755. [Google Scholar] [CrossRef]
- Katzenstein, H.M.; Chang, K.W.; Krailo, M.; Chen, Z.; Finegold, M.J.; Rowland, J.; Reynolds, M.; Pappo, A.; London, W.B.; Malogolowkin, M.; et al. Children’s Oncology Group. Amifostine does not prevent platinum induced hearing loss associated with the treatment of children with hepatoblastoma: A report of the Intergroup Hepatoblastoma Study P9645 as a part of the Children’s Oncology Group. Cancer 2009, 115, 5828–5835. [Google Scholar] [CrossRef]
- Neuwelt, E.A.; Gilmer-Knight, K.; Lacy, C.; Nicholson, H.S.; Kraemer, D.F.; Doolittle, N.D.; Hornig, G.W.; Muldoon, L.L. Toxicity profile of delayed high dose sodium thiosulfate in children treated with carboplatin in conjunction with blood–brain barrier disruption. Pediatr. Blood Cancer 2006, 47, 174–182. [Google Scholar] [CrossRef]
- Duval, M.; Daniel, S. Meta-analysis of the efficacy of amifostine in the prevention of cisplatin ototoxicity. J. Otolaryngol. Head Neck Surg. 2012, 41, 309–315. [Google Scholar] [PubMed]
- Doolittle, N.D.; Muldoon, L.L.; Brummett, R.E.; Tyson, R.M.; Lacy, C.; Bubalo, J.S.; Kraemer, D.F.; Heinrich, M.C.; Henry, J.A.; Neuwelt, E.A.; et al. Delayed sodium thiosulfate as an otoprotectant against carboplatin-induced hearing loss in patients with malignant brain tumors. Clin. Cancer Res. 2001, 7, 493–500. [Google Scholar] [PubMed]
- Freyer, D.R.; Chen, L.; Krailo, M.D.; Knight, K.; Villaluna, D.; Bliss, B.; Pollock, B.H.; Ramdas, J.; Lange, B.; Van Hoff, D.; et al. Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): A multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2017, 18, 63–74. [Google Scholar] [CrossRef]
- Brock, P.R.; Maibach, R.; Childs, M.; Rajput, K.; Roebuck, D.; Sullivan, M.J.; Laithier, V.; Ronghe, M.; Dall’Igna, P.; Hiyama, E.; et al. Sodium thiosulfate for protection from cisplatin-induced hearing loss. N. Engl. J. Med. 2018, 378, 2376–2385. [Google Scholar] [CrossRef]
- Campbell, K.C.; Meech, R.P.; Klemens, J.J.; Gerberi, M.T.; Dyrstad, S.S.; Larsen, D.L.; Mitchell, D.L.; El-Azizi, M.; Verhulst, S.J.; Hughes, L.F.; et al. Prevention of noise- and drug-induced hearing loss with D-methionine. Hear. Res. 2007, 226, 92–103. [Google Scholar] [CrossRef]
- Riga, M.G.; Chelis, L.; Kakolyris, S.; Papadopoulos, S.; Stathakidou, S.; Chamalidou, E.; Xenidis, N.; Amarantidis, K.; Dimopoulos, P.; Danielides, V.; et al. Transtympanic injections of N-acetylcysteine for the prevention of cisplatin-induced ototoxicity: A feasible method with promising efficacy. Am. J. Clin. Oncol. 2018, 36, 1–6. [Google Scholar] [CrossRef]
- Crabb, S.J.; Martin, K.; Abab, J.; Ratcliffe, I.; Thornton, R.; Lineton, B.; Ellis, M.; Moody, R.; Stanton, L.; Galanopoulou, A.; et al. COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss. Eur. J. Cancer 2017, 87, 75–83. [Google Scholar] [CrossRef]
- Freyer, D.R.; Brock, P.; Knight, K.; Reaman, G.; Cabral, S.; Robinson, P.D.; Sung, L. Interventions for cisplatin-induced hearing loss in children and adolescents with cancer. Lancet Child. Adolesc. Health 2019, 3, 578–584. [Google Scholar] [CrossRef]
Age | Tests |
---|---|
Children younger 7–8 months and not cooperative patients | OAEs measurement |
ABR | |
Children between ages of 7–8 months and 24–30 months | Visual reinforcement audiometry |
Children aged 24 months to 5 or 6 years old | Conditioned play audiometry |
Children over 7–8 years old | Pure tone audiometry |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Romano, A.; Capozza, M.A.; Mastrangelo, S.; Maurizi, P.; Triarico, S.; Rolesi, R.; Attinà, G.; Fetoni, A.R.; Ruggiero, A. Assessment and Management of Platinum-Related Ototoxicity in Children Treated for Cancer. Cancers 2020, 12, 1266. https://doi.org/10.3390/cancers12051266
Romano A, Capozza MA, Mastrangelo S, Maurizi P, Triarico S, Rolesi R, Attinà G, Fetoni AR, Ruggiero A. Assessment and Management of Platinum-Related Ototoxicity in Children Treated for Cancer. Cancers. 2020; 12(5):1266. https://doi.org/10.3390/cancers12051266
Chicago/Turabian StyleRomano, Alberto, Michele Antonio Capozza, Stefano Mastrangelo, Palma Maurizi, Silvia Triarico, Rolando Rolesi, Giorgio Attinà, Anna Rita Fetoni, and Antonio Ruggiero. 2020. "Assessment and Management of Platinum-Related Ototoxicity in Children Treated for Cancer" Cancers 12, no. 5: 1266. https://doi.org/10.3390/cancers12051266
APA StyleRomano, A., Capozza, M. A., Mastrangelo, S., Maurizi, P., Triarico, S., Rolesi, R., Attinà, G., Fetoni, A. R., & Ruggiero, A. (2020). Assessment and Management of Platinum-Related Ototoxicity in Children Treated for Cancer. Cancers, 12(5), 1266. https://doi.org/10.3390/cancers12051266